Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients.
To determine the role of human metapneumovirus (HMPV) in respiratory tract infections (RTIs) of lung transplant recipients, 60 patients were prospectively enrolled in this study spanning from September 2005 to November 2007. Community-acquired respiratory viruses (CARVs) were identified by polymerase chain reaction and tissue culture in respiratory secretions. Of 112 RTIs, 51 were associated with > or =1 CARV, including 7 HMPV, 13 respiratory syncytial virus (RSV), 19 parainfluenza virus 1, 2, or 3 (PIV), 16 influenza A or B (FLU), and 3 human rhinoviruses (HRV). Sixteen CARV-RTIs had multiple pathogens. While the standard protocol was to admit all paramyxoviral RTIs for inhaled ribavirin, 16% CARV-RTIs required hospitalization because of the severity of their respiratory compromise, including 25% of HPMV-single-agent RTI, 38% of RSV single-agent RTI, 10% of PIV-single-agent RTI, and 19% of multiple-agent RTIs. None of those with non-CARV RTIs required hospitalization. The incidence of clinically diagnosed acute graft rejection in the first 2 months after an RTI varied from 0 for single-agent HRV to 88% for single-agent RSV (25% for single-agent HMPV). A new diagnosis of chronic graft rejection in the first year after an RTI was made in approximately 25% of the RTIs and did not significantly vary with the etiologic agent. No deaths occurred during this study. In conclusion, HMPV was associated with 6% of the RTIs in lung transplant recipients and its morbidity was similar to the average moribidity of CARVs.
Weinberg
A
A
Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045,, USA. adriana.weinberg@ucdenver.edu
Lyu
D M
DM
Li
S
S
Marquesen
J
J
Zamora
M R
MR
D000328:Adult; D000368:Aged; D017714:Community-Acquired Infections / Q000453:epidemiology / Q000821:virology; D005260:Female; D006084:Graft Rejection; D006760:Hospitalization; D006801:Humans; D015994:Incidence; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D029121:Metapneumovirus / Q000145:classification / Q000235:genetics / Q000302:isolation & purification*; D008875:Middle Aged; D018184:Paramyxoviridae Infections / Q000453:epidemiology / Q000821:virology; D016133:Polymerase Chain Reaction / Q000379:methods; D012137:Respiratory System / Q000821:virology; D012141:Respiratory Tract Infections / Q000453:epidemiology / Q000821:virology; D014777:Virus Diseases / Q000453:epidemiology / Q000821:virology; D014780:Viruses / Q000145:classification / Q000235:genetics / Q000302:isolation & purification
Am J Respir Crit Care Med. 2008 Oct 15;178(8):876-81
18658110
J Heart Lung Transplant. 2007 Dec;26(12):1229-42
18096473
J Infect Dis. 2005 Sep 15;192(6):1061-5
16107960
J Clin Microbiol. 2007 Feb;45(2):548-52
17065270
J Immunol. 2006 Mar 1;176(5):2691-6
16493023
J Clin Microbiol. 1999 Jan;37(1):1-7
9854054
Semin Thorac Cardiovasc Surg. 2004 Winter;16(4):342-9
15635538
Radiology. 1999 Dec;213(3):735-42
10580947
Clin Infect Dis. 2003 Dec 15;37(12):1705-10
14689355
J Heart Lung Transplant. 1993 Sep-Oct;12(5):713-6
8241207
J Infect Dis. 2003 Mar 1;187(5):785-90
12599052
Bone Marrow Transplant. 2003 Feb;31(4):309-10
12621469
J Clin Microbiol. 1997 Jul;35(7):1791-3
9196195
J Clin Microbiol. 1998 May;36(5):1388-91
9574711
Chest. 1998 Apr;113(4):944-50
9554629
J Clin Microbiol. 2003 Jul;41(7):2987-91
12843031
J Heart Lung Transplant. 2005 Nov;24(11):1891-901
16297797
Transpl Infect Dis. 2009 Aug;11(4):304-12
19422670
Am J Respir Crit Care Med. 2002 Aug 15;166(4):440-4
12186817
Nat Med. 2001 Jun;7(6):719-24
11385510
J Med Virol. 2003 Jun;70(2):228-39
12696109
Am J Respir Crit Care Med. 2004 Jul 15;170(2):181-7
15130908
Am J Transplant. 2005 Aug;5(8):2031-6
15996256
Emerg Infect Dis. 2003 Mar;9(3):372-5
12643835
J Clin Virol. 2002 Aug;25(2):171-5
12367651